<DOC>
	<DOCNO>NCT00001014</DOCNO>
	<brief_summary>To compare safety effectiveness investigational drug therapy ( trimetrexate plus leucovorin calcium ) conventional therapy ( sulfamethoxazole-trimethoprim ) treatment moderately severe Pneumocystis carinii pneumonia ( PCP ) patient AIDS , HIV positive , high risk HIV infection . New treatment need reduce mortality rate PCP AIDS patient reduce high relapse rate find conventional therapy . Trimetrexate ( TMTX ) choose trial find much potent sulfamethoxazole/trimethoprim ( SMX/TMP ) PCP organism laboratory test . Also TMTX , combination leucovorin ( LCV ) , cause severe toxicity preliminary trial . It believe TMTX effective treat PCP prevent recurrence PCP .</brief_summary>
	<brief_title>Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim Treatment Pneumocystis Carinii Pneumonia ( PCP ) Patients With AIDS</brief_title>
	<detailed_description>New treatment need reduce mortality rate PCP AIDS patient reduce high relapse rate find conventional therapy . Trimetrexate ( TMTX ) choose trial find much potent sulfamethoxazole/trimethoprim ( SMX/TMP ) PCP organism laboratory test . Also TMTX , combination leucovorin ( LCV ) , cause severe toxicity preliminary trial . It believe TMTX effective treat PCP prevent recurrence PCP . Patients enter study randomly assign trimetrexate / leucovorin ( TMTX / LCV ) sulfamethoxazole/trimethoprim ( SMX/TMP ) 21-day trial . For first 10 day , trial double-blind ( neither patient physician know drug patient receive ) , drug give intravenous infusion . TMTX give every 24 hour LCV every 6 hour ; SMX/TMP give every 6 hour . Doses determine body size . After first 10 day , LCV SMX/TMP may give orally . Doses adjust treatment change intravenous pentamidine side effect severe . During 21-day trial , zidovudine ( AZT ) may use possible increase bone marrow toxicity . AZT may resume soon patient 's white cell count acceptable . Drug therapy aim prevent recurrence PCP allow minimum 4 week completion study therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acetaminophen 650 mg prescribe necessary temperature &gt; 38.7 degree C. Acetaminophen q4h prescribe stand order 48 hour . Prior Medication : Allowed : Zidovudine long therapy suspend prior randomization reinstituted therapy acute episode complete . Prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Unequivocal diagnosis Pneumocystis carinii pneumonia ( PCP ) morphologic confirmation three typical P. carinii organism sputum , bronchoalveolar lavage fluid , lung tissue obtain transbronchial openlung biopsy within 3 day randomization . If morphologic confirmation possible prior therapy , patient may randomize investigator believe high suspicion PCP base clinical presentation . If morphologic diagnosis establish within 6 day randomization , patient withdrawn study therapy . Resting alveolararterial oxygen difference = &gt; 30 mm Hg room air . Exclusion Criteria Patients follow exclude : Inability alveolar blood gas analysis room air . Medically unable receive liter intravenous fluid ( 5 percent dextrose water ) per 24 hour . This procedure require order maintain blinding . Prior Medication : Excluded within 14 day study entry : Systemic steroid exceed physiological replacement . Other investigational drug . Excluded within 6 week study entry : Antiprotozoal regimen episode consist pentamidine , eflornithine , DFMO , dapsone , therapy active Pneumocystis carinii pneumonia ( PCP ) History Type I hypersensitivity ( i.e. , urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction secondary antibiotic contain sulfa , trimethoprim , trimetrexate . History lifethreatening pentamidine toxicity . Requirement treatment agent know myelosuppressive nephrotoxic period acute Pneumocystis carinii pneumonia ( PCP ) therapy . Other drug treatment prevention AIDS Pneumocystis carinii pneumonia ( PCP ) ; disulcid ; aspirin ; acetaminophen q4h 48 hour .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Trimetrexate</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>